Chris Howerton
Stock Analyst at Jefferies
(2.62)
# 2,241
Out of 5,006 analysts
70
Total ratings
45.45%
Success rate
17.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $5.20 | +53.85% | 5 | Jan 2, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $79 | $28.68 | +175.45% | 2 | Sep 29, 2023 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $2.12 | +89.13% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $10 | $4.04 | +147.52% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $2.55 | +13,703.92% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $14.00 | +5,042.86% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $1.79 | -71.99% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $17.05 | -41.35% | 1 | Feb 8, 2023 | |
| AVDL Avadel Pharmaceuticals | Upgrades: Buy | $6.5 → $11 | $14.52 | -24.24% | 3 | Nov 30, 2022 | |
| APLS Apellis Pharmaceuticals | Downgrades: Hold | $70 → $40 | $24.38 | +64.07% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $26.59 | +129.41% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $120.00 | -25.00% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $24 → $12 | $5.40 | +122.22% | 11 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $0.48 | +4,051.96% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $26.37 | +150.28% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $5.47 | +302.19% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $2.05 | +926.89% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $2.03 | +983.74% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.62 | +1,319.75% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $21.59 | -2.73% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $21.00 | +2,661.90% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $0.99 | +5,960.61% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $89.85 | -82.19% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $64.10 | -57.88% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,200 | $8.09 | +14,733.13% | 1 | May 26, 2020 |
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $5.20
Upside: +53.85%
Structure Therapeutics
Sep 29, 2023
Maintains: Buy
Price Target: $50 → $79
Current: $28.68
Upside: +175.45%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $2.12
Upside: +89.13%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $10
Current: $4.04
Upside: +147.52%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $2.55
Upside: +13,703.92%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $14.00
Upside: +5,042.86%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $1.79
Upside: -71.99%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $17.05
Upside: -41.35%
Avadel Pharmaceuticals
Nov 30, 2022
Upgrades: Buy
Price Target: $6.5 → $11
Current: $14.52
Upside: -24.24%
Apellis Pharmaceuticals
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $24.38
Upside: +64.07%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $26.59
Upside: +129.41%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $120.00
Upside: -25.00%
Feb 25, 2022
Downgrades: Hold
Price Target: $24 → $12
Current: $5.40
Upside: +122.22%
Nov 30, 2021
Initiates: Buy
Price Target: $20
Current: $0.48
Upside: +4,051.96%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $26.37
Upside: +150.28%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $5.47
Upside: +302.19%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $2.05
Upside: +926.89%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $2.03
Upside: +983.74%
Apr 19, 2021
Initiates: Buy
Price Target: $23
Current: $1.62
Upside: +1,319.75%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $21.59
Upside: -2.73%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $21.00
Upside: +2,661.90%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $0.99
Upside: +5,960.61%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $89.85
Upside: -82.19%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $64.10
Upside: -57.88%
May 26, 2020
Initiates: Buy
Price Target: $1,200
Current: $8.09
Upside: +14,733.13%